NCT03410901View on ClinicalTrials.gov

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

October 9, 2024

Study Completion Date

October 10, 2024

Conditions
B-Cell Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone LymphomaSmall Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Anti-OX40 Antibody BMS 986178

Given IV, intratumoral

OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

TLR9 Agonist SD-101

Given intratumorally

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ronald Levy

OTHER

NCT03410901 - TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | Biotech Hunter | Biotech Hunter